Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma.
Joaquim BellmuntAly-Khan A LalaniSussana JacobusStephanie A WankowiczLaura PolacekDavid Y TakedaLauren C HarshmanNikhil WagleIrene MorenoKevin LundgrenDominick BosséEliezer M Van AllenToni K ChoueiriJonathan E RosenbergPublished in: British journal of cancer (2018)
Combination therapy with E/P is safe in mUC and select patients with alterations in mTOR or FGFR pathways derive significant clinical benefit.